Bumetanide has a more favourable effect on insulin resistance than furosemide in patients with heart failure - a pilot study

Trial Profile

Bumetanide has a more favourable effect on insulin resistance than furosemide in patients with heart failure - a pilot study

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2014

At a glance

  • Drugs Bumetanide (Primary) ; Furosemide (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Dec 2010 Planned end date changed from 1 Dec 2010 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 01 Aug 2008 The expected completion date for this trial is now 1 Dec 2010.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top